RMTI ROCKWELL MED INC revenue, earnings and financials

For the quarter ended June 30, 2026, ROCKWELL MED INC reported revenue of $17.8M (up 10.6% from a year earlier), net income of −$1.17M and diluted EPS of n/a; over the last four quarters revenue was $69.4M and net income −$5.08M; for the fiscal year ended December 2025 revenue was $69.3M, down 31.8% on the year before.

RMTI annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $69.3M, gross profit $11.7M, operating income −$4.69M, net income −$5.31M (margin -7.7%), EPS −$0.15
• Fiscal year ended Dec 2024: revenue $101M, gross profit $17.5M, operating income $608K, net income −$480K (margin -0.5%), EPS −$0.03
• Fiscal year ended Dec 2023: revenue $83.6M, gross profit $8.70M, operating income −$6.67M, net income −$8.44M (margin -10.1%), EPS −$0.37
• Fiscal year ended Dec 2022: revenue $72.8M, gross profit $4.08M, operating income −$16.8M, net income −$18.7M (margin -25.7%), EPS −$1.31
• Fiscal year ended Dec 2021: revenue $61.9M, gross profit −$2.42M, operating income −$30.3M, net income −$32.7M (margin -52.8%), EPS −$3.83

RMTI quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $17.8M (up 10.6% year over year), net income −$1.17M, EPS n/a
• Quarter ended Mar 31, 2026: revenue $17.3M (down 8.3% year over year), net income −$1.61M, EPS −$0.04
• Quarter ended Dec 31, 2025 (from the annual report): revenue $18.3M (down 25.6% year over year), net income −$554K, EPS −$0.01
• Quarter ended Sep 30, 2025: revenue $15.9M (down 43.8% year over year), net income −$1.75M, EPS −$0.05
• Quarter ended Jun 30, 2025: revenue $16.1M (down 37.8% year over year), net income −$1.49M, EPS −$0.05
• Quarter ended Mar 31, 2025: revenue $18.9M (down 16.6% year over year), net income −$1.52M, EPS −$0.04
• Quarter ended Dec 31, 2024 (from the annual report): revenue $24.7M (up 11.6% year over year), net income −$756K, EPS −$0.02
• Quarter ended Sep 30, 2024: revenue $28.3M (up 19.1% year over year), net income $1.66M, EPS $0.04
• Quarter ended Jun 30, 2024: revenue $25.8M (up 42.9% year over year), net income $343K, EPS $0.01
• Quarter ended Mar 31, 2024: revenue $22.7M (up 15.3% year over year), net income −$1.73M, EPS −$0.06
• Quarter ended Dec 31, 2023 (from the annual report): revenue $22.1M (up 14.4% year over year), net income −$1.51M, EPS −$0.02
• Quarter ended Sep 30, 2023: revenue $23.8M (up 27.2% year over year), net income −$1.87M, EPS −$0.07
• Quarter ended Jun 30, 2023: revenue $18.1M (down 3.2% year over year), net income −$3.31M, EPS −$0.18
• Quarter ended Mar 31, 2023: revenue $19.7M (up 22.0% year over year), net income −$1.75M, EPS −$0.10
• Quarter ended Dec 31, 2022 (from the annual report): revenue $19.3M (up 26.0% year over year), net income −$2.36M, EPS $0.19
• Quarter ended Sep 30, 2022: revenue $18.7M (up 16.9% year over year), net income −$4.19M, EPS −$0.23
• Quarter ended Jun 30, 2022: revenue $18.7M (up 23.4% year over year), net income −$4.97M, EPS −$0.43
• Quarter ended Mar 31, 2022: revenue $16.1M (up 4.2% year over year), net income −$7.16M, EPS −$0.84
• Quarter ended Dec 31, 2021 (from the annual report): revenue $15.3M, net income −$8.94M, EPS −$1.04
• Quarter ended Sep 30, 2021: revenue $16.0M, net income −$7.58M, EPS −$0.89

RMTI cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$659K, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow $4.20M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$9.41M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$16.9M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$33.5M, share buybacks n/a

RMTI balance sheet

• Jun 30, 2026: cash $10.5M, total assets $56.5M, total liabilities $21.4M, shareholders' equity $35.1M, long-term debt $7.24M
• Mar 31, 2026: cash $9.61M, total assets $57.4M, total liabilities $21.6M, shareholders' equity $35.9M, long-term debt $8.21M
• Dec 31, 2025: cash $10.7M, total assets $57.1M, total liabilities $20.2M, shareholders' equity $37.0M, long-term debt $8.83M
• Sep 30, 2025: cash $13.6M, total assets $57.5M, total liabilities $20.5M, shareholders' equity $37.0M, long-term debt $8.74M
• Jun 30, 2025: cash $12.5M, total assets $52.6M, total liabilities $22.2M, shareholders' equity $30.4M, long-term debt $8.65M
• Mar 31, 2025: cash $11.4M, total assets $54.0M, total liabilities $22.4M, shareholders' equity $31.5M, long-term debt $8.56M
• Dec 31, 2024: cash $15.7M, total assets $59.2M, total liabilities $26.6M, shareholders' equity $32.6M, long-term debt $8.47M
• Sep 30, 2024: cash $12.3M, total assets $57.1M, total liabilities $27.9M, shareholders' equity $29.1M, long-term debt $8.38M

What is RMTI's revenue?

ROCKWELL MED INC reported $69.4M of revenue over its last four quarters, through June 30, 2026.

Is RMTI profitable?

No. ROCKWELL MED INC lost $5.08M over the last four quarters.

RMTI ownership and insider trades · All stocks